NomosLogic

Privacy Policy

NomosLogic Master Policy Agreement

Effective Date: January 1, 2026 · Version 1.0

1. Data Privacy & Sovereign Ownership

You remain the sole owner of your raw genetic data (SNPs) and metabolic biomarkers. NomosLogic acts as a data custodian with no ownership claims.

We do not, and will never, sell, lease, or rent individual-level health data to pharmaceutical companies, insurance providers, or third-party advertisers without explicit opt-in.

Upon deletion, identifiable genetic data is purged within thirty days per the Delaware Personal Data Privacy Act.

2. HIPAA & Security Standards

All data is encrypted with AES-256 at rest and TLS 1.2+ in transit. Data used for system improvement is stripped of PII and assigned non-referential UUIDs.

NomosLogic voluntarily adheres to HIPAA Security and Privacy Rules for Protected Health Information.

3. Clinical Boundary and Intended Use

NomosLogic is molecular medicine infrastructure. It provides deterministic genomic interpretation, evidence-anchored analysis, and structured decision-support output intended to improve the clarity, traceability, and usability of molecular findings. It is not a substitute for direct clinical evaluation, diagnosis, or treatment by a licensed healthcare professional, and use of the platform does not create a physician-patient relationship.

Platform findings should be interpreted in the context of the full clinical picture. Decisions involving medication changes, treatment selection, or other medical management should be made with a qualified licensed clinician.

4. Data Usage & Ingestion

Uploading lab PDFs or connecting EHR authorizes Biomarker Analysis Module parsing. Wearable connections (Apple Health, Oura) are optional and revocable through settings.

5. Limitation of Liability & Indemnity

NomosLogic is not liable for indirect, incidental, or consequential damages arising from platform use. Users indemnify the company from claims arising from agreement breach or misuse.

6. Mandatory Arbitration & Class Action Waiver

Disputes shall be resolved through binding arbitration in Salt Lake City, Utah or Wilmington, Delaware. Users waive the right to participate in class-action lawsuits or class-wide arbitration.

7. AI and Automated Processing Disclosure

The platform may include automated computational and software-assisted features used to organize, prioritize, summarize, or present information. Such features are supportive in nature and are not, by themselves, medical advice, diagnosis, or treatment recommendations. Users should not rely solely on automated output when making healthcare decisions.

8. Governing Law

This agreement is governed by the laws of the State of Delaware without regard to conflict of law principles.